Polaryx Secures $10M PIPE to Advance Rare Disease Trial — Polaryx Therapeutics, Inc.

Event summary

Polaryx Therapeutics closed a $10M private placement equity financing on May 28, 2026.
The financing consisted of 2,502,696 shares of common stock at an average price of $4.00 per share.
Proceeds will fund the Phase 2 SOTERIA trial for PLX-200 across four lysosomal storage disorders.
The trial is expected to launch in the second half of 2026 with sites in the U.S., Europe, and Asia.
The financing extends Polaryx's operating runway through Q2 2027.

The big picture

Polaryx's $10M PIPE financing underscores investor confidence in the company's approach to treating rare lysosomal storage disorders. The funding supports the SOTERIA trial, a critical step in validating PLX-200's potential across multiple indications. This move aligns with broader trends in biotech financing, where targeted therapies for rare diseases are attracting significant capital. The trial's success could position Polaryx as a key player in the LSD treatment landscape.

What we're watching

Trial Execution: Whether Polaryx can successfully launch and complete the SOTERIA trial across multiple regions and indications.
Regulatory Pathway: How the FDA's Fast Track Designation will influence the development and approval process for PLX-200.
Financial Runway: The pace at which Polaryx will need to secure additional funding to support operations beyond Q2 2027.